MedTrace Logo

Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients

NCT00417144 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2006-12-29

No results posted yet for this study

Summary

The purpose of this study is to compare pregnancy rates and the occurrence of OHSS in PCOS patients who were treated with GnRH agonist and GnRH antagonist protocols ovarian stimulation during an IVF cycle. Our hypothesis is that the GnRH antagonist protocol reduces the occurrence and severity of OHSS compared to the GnRH agonist protocol.

Conditions

  • Polycystic Ovary Syndrome
  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Arvekap 0.1mg (Triptorelin, Ipsen, France)

DRUG

Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)

Sponsors & Collaborators

  • Eugonia

    lead OTHER

Principal Investigators

  • Tryfon Lainas, PhD · Eugonia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-11-30
Completion
2007-05-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00417144 on ClinicalTrials.gov